China-based pharmaceutical company Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that the Investigational New Drug (IND) filing for its novel injectable PL002 has been accepted for review by the US Food and Drug Administration (FDA). The drug is indicated for preoperative diagnosis and intraoperative navigation in patients with primary liver cancer, marking a significant step towards enhancing surgical outcomes for this condition.
PL002: A Bimodal Contrast Agent
PL002, developed in-house by Hainan Poly Pharm, is a fluorescent/magnetic resonance bimodal contrast agent. This innovative approach has the potential to significantly improve the efficiency of primary liver cancer surgery. The dual capabilities of PL002 offer a comprehensive diagnostic and navigational tool for surgeons.
Dual Functionality in Cancer Surgery
The fluorescence imaging ability of PL002 allows for real-time fluorescence navigation during liver cancer surgery, aiding in the precise identification and removal of cancerous tissue. Additionally, its magnetic resonance enhancement ability provides a preoperative assessment of liver metabolism, enabling speculation on the uptake of contrast agents by the tumor and liver. This dual functionality aims to improve tumor diagnosis accuracy and reduce the difficulty of preoperative planning, ultimately enhancing the effectiveness of liver cancer surgery.-Fineline Info & Tech
